Scleroderma Global Market Report 2023 – By Treatment (Medication, Surgery, Other Treatments), By Indication (Systemic Scleroderma, Localized Scleroderma), By End User (Hospital, Pharmaceutical Stores, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Autoimmune treatment refers to the management and care of a patient for the purpose of combating an autoimmune disease or disorder. This is a type of condition in which one's immune system starts attacking its own body cells. The autoimmune treatment is used to treat autoimmune diseases. The main types of products in autoimmune treatment are consumables and assay kits, instruments, and services. Consultation refers to seeking assistance from another physicians or health care professionals for diagnostic studies, therapeutic interventions, or other services. Diagnosis is the process of identifying the nature of an illness or other problem by examination of the signs and symptoms. The main service types include consultation and diagnosis, therapy and monitoring, and drug development that involve several diseases such as rheumatoid arthritis, systemic lupus erythematosus, sjögren’s syndrome, thyroiditis, scleroderma, and others. The main drug classes include anti-inflammatory, anti-hyperglycemics, NSAIDs, interferons, and others. The main end user are clinical laboratories, hospitals, and others. The global autoimmune treatment market is segmented – 1) By Product: Consumables and Assay Kits, Instruments, Services 2) By Service Type: Consultation and Diagnosis, Therapy and monitoring, Drug development 3) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases 4) By Drug Class: Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs, Interferons, Other Drug Class 5) By End User: Clinical Laboratories, Hospitals, Other End Users The global autoimmune treatment market size is expected to grow from $6.08 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of autoimmune treatment is expected to grow to $10.98 billion in 2027 at a CAGR of 12.5%. The increase in investments in research and development of drugs for autoimmune diseases are expected to propel the growth of the autoimmune treatment market going forward. Research and development are the actions businesses take to innovate and launch new goods and services. Research and development of drugs for autoimmune diseases allows for the development of more targeted, low-molecular-weight, orally active, and chemically characterized immune suppressive drugs with acceptable tolerability in the context of long-term autoimmune disease treatment. For instance, in January 2020, Kyverna Therapeutics, a US-based biotechnology and cell therapy company, raised $25 million series A funding from Vida Ventures and Westlake Village Bio Partners investors and entered into a strategic partnership with Gilead Sciences. This funding will be used to enhance Kyverna's treatment strategy, which integrates advanced T cell engineering and synthetic biology technologies to inhibit and remove autoreactive immune cells, which are the source of inflammatory diseases. Therefore, the increasing investments in research and development of drugs drives the autoimmune treatment market growth. Major players in the autoimmune treatment market are Abbott Laboratories, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, Roche, AstraZeneca Plc, Bristol-Myers Squibb Co., Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK plc, and Genentech Inc. Technological advancements are a key trend gaining popularity in the autoimmune treatment market. Major companies operating in the market are developing advanced technologies to sustain their position in the market. For instance, in January 2020, Predicta Med, an Israel-based healthcare company operating in the autoimmune treatment market, launched Predicta Med which helps in the identification of autoimmune disorders for early detection and intervention. The artificial intelligence technology and machine learning helps to greatly speed up a procedure that generally requires more than four years and at least four different doctors. Also, the accuracy rate increases to 84%, and it can also accurately detect lupus, multiple sclerosis, psoriatic arthritis, and rheumatoid arthritis. This unique platform offers healthcare professionals an AI-powered way of expediting the diagnosis of autoimmune illnesses, which might improve provider efficiency, increase the efficacy of treatment, and improve patient care. In October 2020, Johnson & Johnson, a US-based pharmaceutical industry company, acquired Momenta Pharmaceuticals, Inc. for an amount of $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to expand their leadership in immune-mediated diseases and drive further growth in the development of autoantibody-driven disorders. Momenta Pharmaceuticals, Inc. is a US-based biotechnology company operating in the autoimmune treatment market. North America was the largest region in the autoimmune treatment market in 2022. The regions covered in the autoimmune treatment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the autoimmune treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The autoimmune treatment includes revenues earned by entities by providing immunosuppressive therapy, biological treatment, immuno-suppressing medications services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The autoimmune treatment market report is one of a series of new reports from The Business Research Company that provides autoimmune treatment statistics, including autoimmune treatment industry global market size, regional shares, competitors with an autoimmune treatment market share, detailed autoimmune treatment market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune treatment industry. This autoimmune treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatology endoscopy devices refer to non-invasive devices enabled with a light source and a magnifying lens for improved visualization of the skin's underlying layers. They are primarily used in the detection of skin disorders, structures, patterns, and lesions. The main types of dermatology endoscopy devices are traditional or analog dermatoscopy and digital dermatoscopy. Analog dermatoscopy is also known as chemiluminescence microscopy (ELM) which uses an analog dermatoscopy with magnifying lenses for detailed examination of skin lesions and these are employed in conjunction with a digital camera or smartphone to capture images for subsequent analysis. The major product category is polarized, non-polarized, and hybrid which uses various light sources such as LED, halogen, xenon, and UV and has different modality such as handheld, headband, and trolley-mounted that are used in various applications such as skin cancer, warts, scabies, and other applications. The global dermatology endoscopy devices market is segmented - 1) By Type: Traditional Or Analogue Dermatoscopes, Digital Dermatoscopes 2) By Product: Polarized, Non-Polarized, Hybrid 3) By Light Source: LED (Light Emitting Diode), Halogen, Xenon, UV (Ultraviolet) 4) By Modality: Handheld, Headband, Trolley-Mounted 5) By Application: Skin Cancer, Warts, Scabies, Other Applications The global dermatology endoscopy devices market size is expected to grow from $1.97 billion in 2022 to $2.13 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatology endoscopy devices market size is expected to reach $2.87 billion in 2027 at a CAGR of 7.7%. The rise in the incidence of skin diseases is expected to propel the growth of the dermatology endoscopy devices market going forward. Skin diseases refer to various problems affecting the skin, including infections caused by bacteria, viruses, fungi, allergens, parasites, skin cancer, and other skin diseases. Dermatology endoscopy devices are used for the inspection of skin conditions such as assessing pigmented skin lesions, non-pigmented skin lesions, scabies splinters, psoriasis or eczema, and others to offer effective treatment for skin diseases. For instance, in February 2023, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with psoriasis and psoriatic arthritis, psoriasis affects more than 3% of the adult population in the United States equates to more than 7.5 million people. Therefore, the rise in the incidence of skin diseases drives the growth of the dermatology endoscopy devices market. Major players in the dermatology endoscopy devices market are AMD Global Telemedicine Inc., Bausch Health Companies Inc., Caliber I.D. - Imaging & Diagnostics Inc., Canfield Scientific Inc., DermLite LLC, DermoScan GmbH, Firefly Global, HEINE Optotechnik GmbH and Co. KG, Illuco Corporation Ltd., JEDMED, MetaOptima Technology Inc., Optilia Instruments AB, Pixience Healthcare Technology Solutions, Rudolf Riester GmbH, ALMA LASERS Ltd., Pro Scope Systems, MeKo Laser Material Processing, Biolitec AG, Genesis Biosystems Inc., and Cynosure. Technological advancements are a key trend gaining popularity in the dermatology endoscopy devices market. Major companies in the dermatology endoscopy devices sector are focused on innovating their products to improve the observation power and sustain their position in the market. For instance, in June 2022, Derma Sensor Inc, a US-based health technology company, introduced Derma Sensor, a skin cancer detection device for primary care. The device uses a type of optical technology called Elastic Scattering Spectroscopy (ESS) to take non-invasive samples of tissue, recording cellular-level information from the skin lesion using hundreds of wavelengths of light, comparable to sonar. The Derma Sensor platform gives output directly to the user, eliminating the need for a laboratory or another physician to interpret the spectral data, as the patented algorithm rapidly assesses the data and provides a result in seconds. In April 2022, EMZ Partners, a Germany-based investment firm acquired a majority stake in FotoFinder Systems GmbH for an undisclosed amount. With this partnership, FotoFinder Systems GmbH plans to expand its product offering and reach new markets. FotoFinder Systems GmbH is a Germany-based company that provides skin visualization equipment such as video dermoscopy to dermatologists, dermatology clinics, hospitals, screening facilities, and research organizations. North America was the largest region in the dermatology endoscopy devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global dermatology endoscopy devices market report during the forecast period. The regions covered in the global dermatology endoscopy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology endoscopy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatology endoscopy devices market consists of sales of epiluminescence microscopy, digital epiluminescence microscopy, and USB video-dermatoscopy devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology endoscopy devices market research report is one of a series of new reports from The Business Research Company that provides dermatology endoscopy devices market statistics, including dermatology endoscopy devices industry global market size, regional shares, competitors with a dermatology endoscopy devices market share, detailed dermatology endoscopy devices market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatology endoscopy devices industry. This dermatology endoscopy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatology lasers refer to light amplification device that is used to stimulate emissions of radiation to treat skin conditions such as birthmarks, scars, and wrinkles. Lasers in dermatology are used to treat many skin diseases, pigmented lesions, skin resurfacing, removal of tattoos, and skin rejuvenation. The main types of dermatology lasers are gas laser machines, semiconductor laser machines, gem laser machines, and other types. A Gas laser machine refers to a laser that creates coherent light by discharging an electric current through a gas and it is used in treating scars, benign growths, and age-related skin conditions in dermatology. Major technologies are dermatology lasers and non-ablative dermatology lasers which are used in various applications such as therapeutic, aesthetic, and other applications in hospitals, skin care clinics, cosmetic surgical centers, and others. The global dermatology lasers market is segmented - 1) By Type: Gas Laser Machine, Semiconductor Laser Machine, Gem Laser Machine, Other Types 2) By Technology: Ablative Dermatology Lasers, Non-Ablative Dermatology Lasers 3) By Application: Therapeutic, Aesthetic, Other Applications 4) By End Users: Hospitals, Skin Care Clinics, Cosmetic Surgical Centres, Other End Users The global dermatology lasers market size is expected to grow from $1.96 billion in 2022 to $2.07 billion in 2023 at a compound annual growth rate (CAGR) of 5.79%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatology lasers market size is expected to reach $2.68 billion in 2027 at a CAGR of 6.65%. The increase in the incidences of skin cancer is expected to propel the growth of the dermatology lasers market going forward. Skin cancer refers to the uncontrolled proliferation of aberrant skin cells that is caused when skin cells are harmed either by tanning beds or frequent U.V. radiation. Dermatology lasers are used to provide high-intensity light that destroys or shrinks pre-skin cancer or skin cancer cells that enables less swelling, less bleeding, and scarring that helps in quicker healing of patients suffering from skin cancer. For instance, in March 2022, according to the report published by the International Agency for Research on Cancer, a France-based cancer agency of the World Health Organization, around 1.5 million skin cancer cases were diagnosed worldwide out of which 325 000 cases were of melanoma globally in the year 2020. Therefore, an increase in the incidences of skin cancer is driving the growth of the dermatology lasers market. Major players in the dermatology lasers market are ALMA LASERS LTD, Lumenis Be Ltd, Cynosure Inc, Quanta System SpA, Candela Corporation, Beijing Sincoheren S&T Development Co Ltd, Koninklijke Philips N.V, Cutera Inc, CryoLife Inc., Canfield Scientific Inc., biolitec ® AG, IPG Photonics Corporation, Miracle Laser & Skin Care, IRIDEX Corporation and Syneron. Technological advancements are a key trend gaining popularity in the dermatology lasers market. Companies operating in the dermatology lasers market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Lutronic Corporation, a US-based medical equipment manufacturing company launched the ‘Derma V Dermatology Platform’ that brings all the significant lasers required by skin specialists daily into a single technology. The Derma V technology consists of a 1064nm laser plus ICD cooling, IntelliTrack, and a 532nm green laser that is used in the treatment of various skin conditions such as skin rejuvenation, pigments, and vascular. Derma V's innovative, contact-based speed sensing technology, IntelliTrack, intelligently detects handpiece movement, delivering precise coverage of the treatment area three times faster than alternative options. Additionally, optimal cryogen-based epidermal protection enables the operator to treat severe vascular lesions with the energy and power required, as well as work quickly and efficiently, while offering comfort without pressure sensitivity or contact gels. In October 2021, Vitruvian Partners LLP, a UK-based investment firm acquired Fotona Holdings for an undisclosed amount. With this acquisition Vitruvian Partners LLP, aims to support Fototna Holdings to expand its business in Asia and the rest of the world with innovative capabilities in the laser market. Fotona Holdings is a Slovenia-based laser manufacturing company that develops laser for various industrial and medical applications. North America was the largest region in the dermatology lasers market in 2022. The regions covered in the global dermatology lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology lasers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The dermatology lasers market includes revenues earned by entities by providing services such as facial rejuvenation, scar treatment, skin cancer, and wound treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The dermatology lasers market consists of sales of pulsed dye dermatology lasers, solid-state dermatology lasers, Ablative lasers, and nonablative lasers to provide dermatology laser treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology lasers market research report is one of a series of new reports from The Business Research Company that provides dermatology lasers market statistics, including dermatology lasers industry global market size, regional shares, competitors with a dermatology lasers market share, detailed dermatology lasers market segments, market trends and opportunities, and any further data you may need to thrive in the dermatology lasers industry. This dermatology lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatitis refer to the inhibitors that treat skin inflammation, which is characterised by itchy rashes on swollen and reddish skin, in the outer layer of the body. It is a general term that describes a common skin irritation. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different routes of administration include topical, oral, and injectable and are used in cancer, blood disorders, chronic diseases, and infectious diseases. It is distributed through various channels such as hospitals, retail pharmacies, drug stores, and online or mail pharmacies. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases The global dermatitis market size will grow from $6.46 billion in 2022 to $6.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global dermatitis is expected to grow to $8.57 billion in 2027 at a CAGR of 5.6%. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan PLC. (Republic of Ireland) and Bristol-Myers Squibb. The strict government regulations are one of the restraints for the dermatitis market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). To find the efficacy and efficiency of the drug, it has to be tried on every type of patient. The effects of certain drugs in adults are quite different than in children, as a reasonable result of the clinical trial cannot be used for the production of drugs that will be served to the children. This hinders the research and requires more effort in clearing regulations set by FDA. For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation complies with the Children’s Health Act of 2000 which requires all children subjected to clinical trials to be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in January 2020, Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, acquired Dermira, Inc. for an amount of $1.1 billion. Through this acquisition, Lebrikizumab, an innovative, experimental monoclonal antibody, has been added to the immunology pipeline and marketed dermatology medicines in the product portfolio of Eli Lilly for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dermira, Inc. is a US-based biopharmaceutical company pioneering in the discovery and development of novel therapies for dermatology patients. The dermatitis market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) which carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products to ensure the safety, quality, and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safe thereby having a positive impact on the dermatitis drugs market. North America was the largest region in the dermatitis market in 2022. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Dermatology medical lasers are used in the treatment of medical conditions related to the skin and for the removal of tattoos, wrinkles and scars. The main devices of dermatology medical lasers are surgical lasers and vascular lasers. Vascular laser is a type of device that is utilized to treat vascular lesions, like port wine stains, spider veins, rosacea, and wrinkles by targeting the vessels in these specific areas. The various applications involved are cancer, hair removal, tattoo removal, resurfacing, and others that are used by various end-users such as hospitals, skincare clinics, and cosmetic surgical centers. The global dermatology medical lasers market is segmented - 1) By Device: Surgical Lasers, Vascular Lasers 2) By End-users: Hospitals, Skin Care Clinics, Cosmetic Surgical Centres 3) By Application: Cancer, Hair Removal, Tattoo Removal, Resurfacing, Other Applications The global dermatology medical lasers market size grew from $3.04 billion in 2022 to $3.59 billion in 2023 at a compound annual growth rate (CAGR) of 17.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global dermatology medical lasers is expected to grow from $6.76 billion in 2027 at a CAGR of 17.2%. The growing demand for cosmetic procedures is expected to drive the dermatology medical lasers market. There has been an increase in the number of people opting for cosmetic procedures to enhance the appearance levels and treatment of defects on the skin. According to the American Society of Plastic Surgeons data, $16.7 billion was spent on cosmetic procedures in the U.S. in 2020. The poll also revealed that 11% of women surveyed said they are more interested in cosmetic plastic surgery or non-surgical procedures than before COVID-19. Dermatology lasers are used in cosmetic procedures such as removal of fine lines, wrinkles, skin tightening, pigmented lesions, precancerous lesions, vascular lesions, tattoos, hair removal, acne scars, and others. Hence, the growing demand for cosmetic procedures among users aids in the growth of the dermatology medical lasers market. Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd., and Cutera. Alternatives for laser skin treatment are expected to hinder the dermatology medical lasers market. The growing popularity of alternative methods of skin treatment such as the use of drugs, chemical treatment, microneedle, and Botox surgery is expected to hinder the growth of the market. For instance, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the demand for surgical and nonsurgical facial plastic surgery treatments increased by 40% as compared to 2020. Thus, the demand for alternatives is expected to restrain the growth. Companies are increasingly investing in Picosecond Lasers for skin treatments other than tattoo removal as they have found their use in the treatment of acne, skin lightening, and skin tightening. For instance, in January 2021, LASEROPTEK Co Ltd received FDA 510(k) clearance for its next-generation PicoLO Premium™ Picosecond ND: YAG Laser. Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market. In March 2020, SemiNex Corporation, a U.S-based high-diode manufacturer, announced its collaboration with Dermal Photonics Corporation, a manufacturer of Nira skincare - a professional home laser technology. Through this collaboration, SemiNex Corporation plans to enhance home-based lasers for dermatology procedures. Dermal Photonics is a US-based medical device company. North America was the largest region in the dermatology medical lasers market in 2022. Asia-Pacific was the second largest region in the dermatology medical lasers market report. The regions covered in the dermatology medical lasers analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the dermatology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The dermatology medical lasers market consists of sales of surgical lasers and vascular lasers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology medical lasers market research report is one of a series of new reports from The Business Research Company that provides dermatology medical lasers market statistics, including dermatology medical lasers industry global market size, regional shares, competitors with a dermatology medical lasers market share, detailed dermatology medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the dermatology medical lasers industry. This dermatology medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatology devices are the equipment used to research, study, manage, and diagnose the health conditions and affecting the skin, nails, membranes, and fat. It is a branch of medicine that deals with skin-related diseases. Dermatology also includes cosmetic care and enhancement of the skin. The dermatology devices are used for treating skin-related problems. The main types of dermatology devices are diagnostic devices, treatment devices, and others. Diagnostic dermatology devices are used for diagnosing skin-related problems. Diagnostic devices are the devices that identify the cause or nature of a medical condition. They are used to monitor and diagnose various vital parameters derived from the body. Some of the diagnostic devices include glucometers, bio-signal recording instruments, patient monitoring systems, pulse oximeters, and others. The various applications include skin cancer diagnosis, psoriasis, skin rejuvenation, warts, and others, which are used by several end users, including hospitals, clinics, and others. The global dermatology devices market is segmented - 1) By Product Type: Diagnostic Devices, Treatment Devices, Other Product Types 2) By Application: Skin Cancer Diagnosis, Psoriasis, Skin Rejuvenation, Warts, Other Applications 3)By End User: Hospitals: Clinics, Other End Users The global dermatology devices market size grew from $12.04 billion in 2022 to $14.03 billion in 2023 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the dermatology devices market is expected to grow to $23.46 billion in 2027 at a CAGR of 13.7%. The increasing prevalence of skin cancer and other skin diseases is expected to propel the growth of the dermatology devices market going forward. Skin cancer is the uncontrolled proliferation of abnormal cells in the epidermis, the outermost layer of the skin. It is caused by malignant tumors formed from unrepaired DNA damage. Other skin-related diseases include eczema, cold sores, dry skin, acne, and others. In order to remove skin tumors, dermatology devices such as light treatment devices, lasers, and electrosurgical equipment are used. For instance, according to the American Cancer Society, a US-based voluntary health organization, in 2022, around 99,780 new melanoma skin cancer cases were diagnosed and around 7,650 patients died due to melanoma, in the US. Therefore, the growing prevalence of skin cancer and other skin diseases is driving the growth of the dermatology devices market. Major players in the dermatology devices market are Cutera Inc., Lumenis Ltd., Alma Lasers, Solta Medical Inc., Aesthetic Group, Ambicare Health, Image Derm Inc., Johnson & Johnson Private Limited, AMD Global Telemedicine Inc., Cortex Technology, HEINE Optotechnik GmbH & Co. KG, Michelson Diagnostics, Bruker Corporation, Bovie Medical Corporation, Illuco Corporation Ltd., Photomedex Inc., and Applisonix Ltd. Technological advancements have emerged as a key trend gaining popularity in the dermatology device market. Major companies operating in the dermatology devices sector are focused on new technological innovations to sustain their position in the market. For instance, in January 2020, 3Derm Systems, Inc., a US-based company that manufactures dermatology devices, launched 3DermSpot. The 3DermSpot is an algorithm designed to use artificial intelligence (AI) and highly standardized skin images to help in autonomously detecting melanoma, squamous cell carcinoma, and basal cell carcinoma. This helps in the speedy detection of skin cancer. In May 2021, Allergan Aesthetics, an Ireland-based pharmaceutical company, acquired Soliton’s for an undisclosed amount. Through this acquisition, Allergan Aesthetics aims to strengthen its portfolio of body contouring treatments. The new RAP device uses a rapid pulse of acoustics to break the fibrous septa band underneath the skin, which causes cellulite and is used to remove tattoos. The device is also being investigated for the treatment of fibrotic scars. Soliton is an Indian-based company that manufactures medical devices, automotives, and robotics and develops dermatology devices technology. North America was the largest region in the dermatology devices market in 2022. Asia-Pacific is the second largest region in the dermatology devices market. The regions covered in the dermatology devices market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatology devices market consists of sales of lasers, light therapy devices, electrosurgical equipment, liposuction devices, cryotherapy devices, and microdermabrasion devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology devices market research report is one of a series of new reports from The Business Research Company that provides dermatology devices market statistics, including dermatology devices industry global market size, regional shares, competitors with a dermatology devices market share, detailed dermatology devices market segments, market trends and opportunities, and any further data you may need to thrive in the dermatology devices industry. This dermatology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermal fillers refer to gel-like medical device implants designed to be injected beneath the surface of the skin for use in helping to create a smoother and fuller appearance in the face. Dermal fillers help to correct moderate-to-severe facial wrinkles and skin folds, increase fullness of lips, cheeks, chin, under-eye hollows, jawline, and back of the hand, and restoring facial fat loss. The main types of dermal fillers are calcium hydroxylapatite, hyaluronic acid, poly-alkylimide, polylactic acid, polymethylmethacrylate microspheres. Calcium Hydroxylapatite dermal fillers are used in moderate-to-severe creases such as nasolabial folds, marionette lines, and frown lines to enhance the fullness of the cheeks and other facial contours. The different products include biodegradable, and non-biodegradable and are used in various applications such as scar treatment, wrinkle correction treatment, lip enhancement, and restoration of volume or fullness. It is employed by numerous end users, including hospitals, cosmetic clinics, outpatient centers, beauty centers, and others. The global dermal filler market is segmented - 1) By Filler Type: Calcium Hydroxylapatite, Hyaluronic Acid, Poly-Alkylimide, Polylactic acid, Polymethylmethacrylate Microspheres 2) By Product: Biodegradable, Non-Biodegradable 3) By Application: Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration Of Volume or Fullness 4) By End-User: Hospital, Cosmetic Clinics, Outpatient Centres, Beauty Centres, Other End Users The global dermal filler market size will grow from $5.44 billion in 2022 to $6.04 billion in 2023 at a compound annual growth rate (CAGR) of 11.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global dermal filler industry is expected to grow to $8.5 billion in 2027 at a CAGR of 8.9%. An increasing number of aesthetic procedures performed by plastic surgeons is expected to drive the growth of the dermal filler market going forward. Aesthetic procedures refer to procedures that improve the face and body appearance. There has been a growing emphasis on the body and beauty for identity and self-expression. Dermal fillers are used majorly in plastic surgery or aesthetic procedures to help create a smoother and fuller appearance on the face. For instance, according to the American Society for Aesthetic Plastic Surgery, in 2021, facial procedures increased by 54% and aesthetic body procedures shot up by 63% from 2020. Therefore, the increasing number of aesthetic procedures performed by plastic surgeons propels the growth of the dermal filler market. Major players in the dermal filler market are Allergan Inc., Anika Therapeutics Inc., BioPlus Co. Ltd., Bioxis Pharmaceuticals, Dr. Korman Laboratories Ltd., Galderma S.A., Medy Tox Inc., Merz Pharma GmbH & Co. KGaA, Prollenium Medical Technologies Inc., Revance Therapeutics Inc., Scivision Biotech Inc., Sculpt Fillers, Sinclair Pharma, Suneva Medical Inc., and Teoxane Laboratories. Technological advancements have emerged as the key trend gaining popularity in the dermal filler market. Companies operating in the dermal filler market are focusing on developing innovative products for market growth. For instance, in April 2021, Sinclair Pharma, a UK-based pharmaceutical company, launched MaiLi, a new hyaluronic acid filler that harnesses the power of OxiFree HA technology for the treatment of medium-sized skin depressions, fine-lines, the periorbital area, and is effective for lip enhancement. MaiLi uses 24% less product for the same volumizing effect. In October 2020, Allergan Aesthetics, an AbbVie Company, a US-based pharmaceutical company, acquired Luminera’s dermal fillers business for an undisclosed amount. The acquisition is expected to enhance Allergan Aesthetics' leading dermal filler portfolio with its JUV DERM collection of fillers along with the innovative technology. Luminera is an Israel-based company that manufactures dermal filler products. North America was the largest region in the dermal filler market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermal filler market analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermal filler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermal filler market consists of sales of autologous fat injections, permanent soft tissue filler. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermal fillers market research report is one of a series of new reports from The Business Research Company that provides dermal filler market statistics, including dermal filler industry global market size, regional shares, competitors with a dermal filler market share, detailed dermal filler market segments, market trends and opportunities, and any further data you may need to thrive in the dermal filler industry. This dermal filler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Dermatology OTC medications are non-prescription drugs used to prevent and cure conditions affecting the skin, hair, nails, mouth, and genitalia. This type of drug is used by the general public safely and effectively without seeking treatment from a health practitioner. The main types of dermatology OTC medications includes tablets and capsules, oils, gels, creams, ointments, and others. A tablet is a tightly packed, solid dosage form containing drugs, either with or without excipients. Additionally, the term capsule designates a solid pharmaceutical dosage form in which a chemical or mixture of substances is enclosed in a gelatin shell or any other suitable material to produce a variety of shapes. An over-the-counter medication called cetirizine is used to treat allergy symptoms like itchy eyes. They are used to treat indications such as dermatitis, acne, psoriasis, skin bleaching, anti-fungal, wart remover, and others. These are mainly administered through topical and oral routes of administration and sold via distribution channels such as online distribution and offline distribution. The global dermatology OTC medications market is segmented - 1) By Type: Tablets And Capsules, Oils Gels, Creams And Ointments, Other Types 2) By Indication: Dermatitis, Acne, Psoriasis, Skin Bleaching, Anti-Fungal, Wart Remover, Other Indications 3) By Route Of Administration: Topical, Oral 4) By Distribution Channel: Online Distribution, Offline Distribution The global dermatology OTC medications market size is expected to grow from $14.76 billion in 2022 to $15.32 billion in 2023 at a compound annual growth rate (CAGR) of 3.86%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of dermatology OTC medications market is expected to reach $18.06 billion in 2027 at a CAGR of 4.20%. The increase in skin abnormalities is expected to propel the growth of the dermatology OTC medication market going forward. A skin abnormality refers to a skin lesion or strange appearance of the skin. In dermatology, over-the-counter drugs are used to treat skin abnormalities and normalize the skin. The demand for over-the-counter dermatology medications is rising as a result of increased treatment requirements for skin abnormalities, including psoriasis. For instance, in August 2021, according to the Centers for Disease Control (CDC), a US federal government agency for the prevention and control of diseases, more than 7.5 million people in the USA and over 125 million people globally suffered from psoriasis, one of the most prevalent chronic cutaneous dermatitis. Therefore, the increase in skin abnormalities is driving the growth of the dermatology OTC medication market. Major players in the dermatology OTC medications market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Bristol Myers Squibb Co, GlaxoSmithKline Plc, Acella Pharmaceuticals LLC, Eli Lilly and Company, Amgen Inc., Allergan plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., Perrigo Company PLC, Galderma S.A., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Lupin Limited, LEO Pharma A/S, Almirall S.A., Concert Pharmaceuticals, Arcutis Biotherapeutics, Dermavant Sciences, and Roivant Sciences Inc. Technological advancements are a key trend gaining popularity in the dermatology OTC medication market. Companies operating in the dermatology OTC medication market are adopting new technology to sustain their position in the market. For instance, in October 2020, Cynosure launched the Potenza Radiofrequency Microneedling Device, the only RF micro needling machine in the world to integrate monopolar and bipolar radiofrequency at 1 or 2 MHz into a single device and produce four distinct RF modes. The gadget has a single-needle handpiece that is equipped to target and treat blemishes and is effective against acne vulgaris. In February 2022, Taro Pharmaceutical Industries Ltd., a US-based pharmaceutical company, acquired Alchemee for an undisclosed amount. This acquisition will help Taro enhance its position in the over-the-counter dermatology market by adding Alchemee's assets and resources, including the Proactiv brand. Taro is also gaining access to the Alchemee team's omnichannel marketing capabilities and knowledge. Alchemee is a US-based health, wellness, and fitness company that specializes in skin health, direct marketing, and acne. North America was the largest region in the dermatology OTC medications market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology OTC medications market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The dermatology OTC medication market consists of sales of roasted moisturizers, shampoo, and acne products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology OTC medications market research report is one of a series of new reports from The Business Research Company that provides dermatology OTC medications statistics, including the dermatology OTC medications industry global market size, regional shares, competitors with a dermatology OTC medications market share, detailed dermatology OTC medications market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatology OTC medications industry. This dermatology OTC medications market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.